Openbookopenbook
Equity
Neuren Pharmaceuticals Limited(NURPF)
USD --+0.00%
Reward64Moderate
Risk47Moderate
📊75%Data
Strong 68% profit margin
NURPF
+0.0 · +0.00%
USD · PINK
Neuren Pharmaceuticals Limited | Healthcare
Quality Compounder
Market Cap:1.10Bn
ℹ️
Reward Rating
64
Moderate
Top 50% (model universe)
75% data coverage
ℹ️
Risk Rating
47
Moderate
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on NURPF to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Neuren Pharmaceuticals Limited?

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders.

NURPF · Verdict

Solid reward · moderate risk

NURPF stands out on balance sheet and profitability, but watch the volatility signal.

Based on 88% data coverage

NURPF · Verdict

What’s working & what to watch

Strengths 3

  • Balance sheet86/100

    Current ratio 8.73

  • Profitability81/100

    66% net margin · 55% ROE

  • Growth78/100

    Revenue +307.8% CAGR

Watchouts 3

  • Volatility20/100

    Weak vs peers

  • Valuation30/100

    P/E 53.2×

  • Cash flow42/100

    -5% free-cash-flow margin

Model-based scoring. For information only — not financial advice.

What is Neuren Pharmaceuticals Limited?

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 1.10B, and a P/E ratio of 10.5x.

Financial Highlights

Investment Breakdown

📈 Growth
Revenue and earnings growing steadily, indicating improving operating performance.
💰 Profitability
Strong margins and consistent earnings support financial stability.
⚠️ Risk
Risk profile appears balanced versus broad market conditions.
💸 Valuation
Premium valuation reflects strong growth expectations already priced in.

OpenBook Logo Analysis

Reward: Moderate (64)

The scoring profile indicates moderate reward potential, with profitability and growth as the leading contributors. Risk indicators are moderate, consistent with typical market exposure.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap1.10B
P/E Ratio10.5247
Dividend YieldN/A
52 Week High14.7965
52 Week Low6.6
Last AnnualDecember
IPO DateN/A
IncorporatedUSA
Shares Outstanding127M
No. of EmployeesN/A
IndustryBiotechnology
ExchangePINK
Beta1.737
CurrencyUSD · Reports in AUD
Websitewww.neurenpharma.com
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.